Midgard Science

Labs / ADME, DMPK & toxicology

ImmuVia

Cambridge, MA, United States · immuvia.com

GLP · GMP

ImmuVia develops targeted apoptosis therapeutics centered on bispecific antibodies that cluster DR5 on tumor cells to induce cell death. It works on solid tumors and leukemia, with programs for MUC16-positive cancers and a partnering platform for new tumor antigens.

They take quote requests by email.

What they offer

  • Discovery and preclinical development of bispecific apoptosis therapeutics

    Develops tumor-targeted antibodies that trigger apoptosis through DR5 super-clustering on cancer cells.

  • IND-enabling development

    Advances lead programs through IND-enabling studies and related de-risking work.

  • Partnering for new tumor targets

    Offers the Cancerlysin platform for applying the same apoptosis mechanism to additional tumor antigens.

What they work on

Modalities
Antibody, Bispecific, ADC
Species and models
NHP, NSCLC, ovarian cancer, pancreatic cancer, colorectal cancer, gastric cancer, acute myeloid leukemia
Assays and studies
cytotoxic activity, safety characterization, in vivo efficacy
Therapeutic areas
NSCLC, ovarian cancer, pancreatic cancer, colorectal cancer, gastric cancer, acute myeloid leukemia
Address
245 First Street, Suite 1800 Cambridge, MA 02142

Similar labs. Aurigene Pharmaceutical Services, Xcellon Biologics, Bio X Cell, Biocytogen

Found in a contract services directory. Listing built from immuvia.com. Work here? Claim this listing.

ImmuVia · Midgard Science